Skip to main content

Table 2 Laboratory parameters in moderately, severely and critically ill COVID-19 patients

From: An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Baseline parameters

Moderately ill Patients

Severely ill patients

Critically ill patients

All patients

p value

(n = 11)

(n = 7)

(n = 6)

Hemoglobin (g/l)

112.4 ± 16.63

104 ± 22.35

90.17 ± 37.73

102.6 ± 27.26

0.744 ANOVA

White blood cell (× 109/L)

6.925 ± 2.842

7.92 ± 2.366

11.08 ± 4.304

8.5 ± 3.599

0.090

K-W

Neutrophil (× 109/L)

4.462 ± 2.055

4.777 ± 3.417

9.537 ± 4.154

5.882 ± 3.712

0.012 ANOVA

Lymphocyte (× 109/L)

1.571 ± 0.6184

1.634 ± 0.689

1.059 ± 0.5516

1.44 ± 0.6363

0.227 ANOVA

NLR

3.825 ± 3.317

6.389 ± 9.717

10.82 ± 6.083

6.433 ± 6.501

0.065

K-W

Platelet (× 109/L)

198.5 ± 41.79

231.2 ± 32.69

311 ± 156.9

224 ± 88.83

0.413 ANOVA

PLR

171.8 ± 154.5

243.2 ± 251.9

226.9 ± 223.4

227.8 ± 195.8

0.208

K-W

Triglycerides (mmol/L)

1.023 ± 0.2329

1.197 ± 0.2871

1.962 ± 1.081

1.408 ± 0.7893

0.080 ANOVA

ALT (U/L)

18.86 ± 13.63

18 ± 15.75

36.67 ± 22.54

24.94 ± 18.84

0.168 ANOVA

D-Dimer (mg/l)

0.92 ± 0.6479

2.07 ± 1.669

1.773 ± 0.7467

1.396 ± 0.924

0.744 ANOVA

  1. Abbreviations: NLR Neutrophil-to-lymphocyte ratio; PLR Platelet-to-lymphocyte ratio; ALT Alanine aminotransferase; ANOVA Analysis of variance; K-W Kruskall-Wallis